Navigation Links
AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
Date:4/15/2008

QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported the completion of patient recruitment for the Company's first efficacy trial of its Phase 3 program in benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate, with its flagship product candidate, cetrorelix. The study involves approximately 600 patients primarily in the United States and Canada, with additional sites in Europe.

"We are very proud to have reached this important milestone. The Phase 3 program in BPH with cetrorelix is on track and we expect to provide results in the third quarter of 2009 as stated previously," commented Paul Blake, M.D., Senior Vice President and Chief Medical Officer of AEterna Zentaris.

This first efficacy study, titled "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1-year placebo-controlled efficacy study and long-term safety assessment", will assess an intermittent dosage regimen of cetrorelix as a safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms.

About the Phase 3 Program with Cetrorelix in BPH

The first multi-center efficacy study commenced first patient randomization in April 2007 and completion of patient recruitment was announced today. It is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves approximately 600 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NY University School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm sever
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris Announces Changes to its Management Team
2. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
3. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
4. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
5. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
6. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
9. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
10. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
11. AEterna Zentaris Announces Outcome of Managements Strategic Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Research and Markets ... Metabolomics Market 2014-2018" report to their offering. ... Metabolomics or Metabonomics is the scientific study ... a new experimental technique that is being widely ... Metabolites are small molecules that are present in ...
(Date:7/25/2014)... California (PRWEB) July 25, 2014 Lawrence ... named to Thomson Reuters list of " The World's ... are part of the 3,000 researchers who were identified ... to recognize those who published the highest-impact work (2002-2012 ... research papers on combustion modeling . , "This ...
(Date:7/25/2014)... BEIJING , July 25, 2014 Sinovac Biotech ... biopharmaceutical products in China , today announced ... second quarter ended June 30, 2014, after market close on ... conference call prior to the market opening on Friday, August ... at 8:00 p.m. China Standard Time) to review the Company,s ...
(Date:7/24/2014)... July 24, 2014  Now available is a stem ... Rehealth Regenerative Therapies , located in Guadalajara, ... active people a new health option: stem cell ... age, countless patients suffer from joint and muscle injuries ... muscle tears, torn rotator cuff, tennis elbow, and knee ...
Breaking Biology Technology:Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... Brad Thompson, President,and CEO of Oncolytics Biotech Inc. (TSX: ... Company at the Maxim Group Growth Conference at,2:30 p.m. ... being held at the,Grand Hyatt Hotel in New York., ... is available at, http://www.wsw.com/webcast/maxim/oncy/ on the company,s website ...
... Engineering and Operations Appointed -, CLINTON, N.J., ... appointment of Michael Kennedy as Senior Vice President,Engineering ... responsible for,drug-device technology strategy and development., "Michael,s ... critical care as we continue to advance our ...
... Oct. 2 ,ImpediMed Ltd, a pioneer in ... Inc., a global leader in science-based,nutraceutical products, ... announced an agreement to distribute ImpediMed technology,in ... affiliate, Health,World, Ltd, has been a long-standing ...
Cached Biology Technology:Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference 2Ikaria Strengthens Executive Leadership Team 2ImpediMed and Metagenics Announce Agreement 2
(Date:7/24/2014)... use of native animal species for food or commercial ... significant factor in the decline of many species of ... indicates that more than half of the species being ... hornbills., "By surveying not only the meat made available ... inside the forest by hunters and brought to villages ...
(Date:7/24/2014)... has identified two factors that characterize sustainable university ... of highly qualified physics teachers. Specifically, one or ... teacher education in combination with institutional motivation and ... Science, Technology, Engineering and Math (STEM) teacher shortages ... points the way for institutions seeking to increase ...
(Date:7/24/2014)... Some sticky research out of York University shows ... species of toxic grass fungus: moose saliva (yes moose ... Letters , "Ungulate saliva inhibits a grassendophyte mutualism" shows ... fescue grass (which hosts a fungus called epichlo festucae ... growth and less toxicity. , "Plants have evolved defense ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Moose drool inhibits growth of toxic fungus: York U research 2
... and a half acres of Appalachia have been strip-mined, whole ... and communities devastated. Not exactly a promising place for a ... For his startling and bold proposal to clean-up this ... of Appalachia, John Todd, a research professor in the Rubenstein ...
... drug reverses the brain dysfunction inflicted by a genetic ... of TSC patients also suffer from autism, the findings ... autism. Nature Medicine publishes the findings ... mouse model for TSC, the scientists tested rapamycin, a ...
... the Smithsonian,s National Zoo detected a secondary rise in ... Mei Xiang (may-SHONG) earlier this month. The results from ... believe the hormone rise indicates that it would be ... to a cub or comes to the end of ...
Cached Biology News:Buckminster Fuller takes on big coal 2Buckminster Fuller takes on big coal 3Drug reverses mental retardation caused by genetic disorder 2